Psychedelic

• Former President Trump signed an executive order in April titled “Accelerating Medical Treatments for Serious Mental Illness” to fast-track research and drug approvals for psychedelic-assisted therapy. • The order aims to increase clinical trial participation and explore innovative research models to treat serious mental health conditions. • This federal push provides a new path for psychedelic research in Missouri, where state lawmakers have failed for several years to pass similar legislation.

• Missouri State Rep. Dave Griffith is advocating for psychedelic-assisted therapy to treat veterans suffering from depression and post-traumatic stress disorder. • The initiative follows an April executive order signed by Donald Trump titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to speed up drug approvals and clinical trial participation. • The order directs the Secretary of Health and Human Services to allocate at least $50 million to support state governments developing programs for psychedelic drugs.

Hope that sessions of MDMA-assisted therapy could help soldiers fight longer by helping them process traumaAs the war on drugs approaches its end, a new doctrine could soon take hold: psychedelic drugs for active-duty soldiers suffering from PTSD.In two studies funded by the Department of Defense (DoD), 186 service personnel with PTSD will likely next year undergo multiple sessions of MDMA-assisted therapy. Continue reading...

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile pushThe Trump administration issued an executive order earlier this month to accelerate access to psychedelic medication for people with “serious mental illnesses,” but experts say the order is more likely to make a difference symbolically than legally.“Policymakers and the medical field have long struggled to address the burden of suicide and serious mental illness rates in America,” the order reads, noting that some people do not respond to available treatments. Continue reading...

Order to speed hallucinogen research hailed as ‘threshold moment’ but concerns remain over access and protectionsThe scene seemed so far-fetched you could be forgiven for thinking you might be hallucinating.On the weekend in which psychonauts celebrate “Bicycle Day” – the anniversary of the first LSD trip – Donald Trump was in the Oval Office double-checking that he was correctly pronouncing the name of a lesser-known psychedelic, ibogaine, as he signed a landmark executive order to accelerate research into hallucinogens, and to increase access. Continue reading...

Use of the illicit drug has plummeted in recent years among gen Zers, compared with their parents’ generationEver since cocaine first emerged as a popular party drug via the shores of Miami in the early 1970s, use of the stimulant has been inextricably entwined with the very essence of capitalist excess and what it is to be American: brash, bombastic and brazen.The wide-scale use of cocaine in the US has left a trail of destruction in its wake, largely thanks to the illegal nature of the trade and the resultant US government policy of a “war on drugs”. Continue reading...

• President Trump has moved to fast-track psychedelic research as part of his administration's policy agenda, marking a significant shift in federal drug policy priorities. • Former Arizona Senator Kyrsten Sinema has publicly applauded the initiative as a "bold step forward" in medical research on Fox & Friends Weekend. • The accelerated psychedelic research program represents an innovative approach to mental health treatment and scientific advancement under the Trump administration.

• The FDA announced it will issue national priority vouchers for three psychedelic drugs next week, marking the first time the agency has fast-tracked any psychedelics for review under Trump's executive order on mental health reform. • The vouchers can compress FDA review timelines from several months to just weeks, according to FDA Commissioner Marty Makary, if the drugs align with national priorities. • Trump's order directs $50 million in federal funding to states developing psychedelic treatment programs and establishes a federal-state partnership for technical assistance and data sharing.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder. Continue reading...

Analysis of more than 500 brain scans finds LSD, psilocybin and other psychedelics increase cross-talk between brain systemsScientists have identified a hallmark signature produced by psychedelic drugs in the human brain when users experience their mind-altering effects.The “neural fingerprint” of the psychedelic trip was spotted among hundreds of brain scans of people on LSD, psilocybin, DMT, mescaline and ayahuasca, pointing to a shared impact on the brain’s behaviour. Continue reading...